Mineralys Therapeutics, INC Form 4 insider transactions

James J. Ferguson Iii, Chief Medical Officer of Mineralys Therapeutics, Inc., reported multiple transactions in common stock on August 10, 2026.

David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, Inc., sold 2,170 shares of common stock on August 10, 2026 for $27.09 per share.

Eric Warren, Chief Commercial Officer of Mineralys Therapeutics, Inc., sold 7,438 shares of common stock on July 21, 2026 for $26.87 per share.

David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, Inc., sold 416 shares of common stock on July 17, 2026 for $26.53 per share.

Jon Congleton, Chief Executive Officer and a Director of Mineralys Therapeutics, Inc., sold 10,700 shares of common stock on July 13, 2026 for $27.24 per share.

David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, Inc., sold 20,407 shares of common stock on July 13, 2026.

David Rodman, Chief Medical Officer of Mineralys Therapeutics, Inc., reported transactions involving the acquisition and disposition of common stock, executed under a Rule 10b5-1 trading plan.

Jon Congleton, CEO of Mineralys Therapeutics, Inc., reported the sale of company stock totaling 75,000 shares under a pre-arranged 10b5-1 trading plan.

Mineralys Therapeutics Chief Commercial Officer Eric Warren sold 104,124 shares of common stock on June 26, 2026, pursuant to a Rule 10b5-1 trading plan.

Chief Medical Officer David Malcom executed stock option exercises and sales under a pre-arranged Rule 10b5-1 trading plan.

Mineralys Therapeutics director Daphne Karydas exercised options and sold 3,000 shares of common stock under a 10b5-1 plan.

Chief Medical Officer David Malcom Rodman exercised and sold shares of Mineralys Therapeutics under a Rule 10b5-1 plan.

Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, executed a planned sale of common stock following an option exercise.

Chief Medical Officer David Rodman sold over 22,000 shares of Mineralys Therapeutics under a pre-arranged trading plan in May 2026.

Chief Medical Officer David Malcom exercised and sold 416 shares of Mineralys Therapeutics under a 10b5-1 trading plan.

Chief Medical Officer David Malcom Rodman exercised stock options and sold shares of Mineralys Therapeutics under a 10b5-1 plan.

Mineralys Therapeutics CEO Jon Congleton sold 15,730 shares of common stock via a pre-arranged 10b5-1 trading plan.

Mineralys Therapeutics Chief Medical Officer, Rodman David Malcom, executed trades involving common stock and stock options under a pre-established Rule 10b5-1 trading plan.

Mineralys Therapeutics CEO Jon Congleton executed a series of stock sales totaling over 75,000 shares, as disclosed in a Form 4 filing.

Director Daphne Karydas executed a Rule 10b5-1 trading plan, acquiring 3,000 shares and selling 3,000 shares of Mineralys Therapeutics, Inc. (MLYS) on March 31, 2026.

Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, executed stock options and subsequently sold 417 common shares as part of a pre-arranged 10b5-1 trading plan.

Mineralys Therapeutics' Chief Medical Officer, David Malcom Rodman, sold common stock following the exercise of stock options under a pre-arranged 10b5-1 trading plan.

An insider associated with RA Capital Management, a significant shareholder and director of Mineralys Therapeutics, was granted restricted stock units and stock options as part of compensation.

Mineralys Therapeutics CEO Jon Congleton received grants of 140,900 Restricted Stock Units and 187,900 stock options.

Mineralys Therapeutics director Glenn Sblendorio was granted 6,200 Restricted Stock Units and options for 8,300 shares of common stock.

Mineralys Therapeutics, Inc. director Alexander M. Gold was granted 6,200 Restricted Stock Units and options for 8,300 shares of common stock.

Mineralys Therapeutics Director Daphne Karydas is set to receive 6,200 Restricted Stock Units and options for 8,300 shares of common stock on February 19, 2026.

Mineralys Therapeutics Director and 10% owner Brian Taylor Slingsby reported the grant and subsequent transfer of Restricted Stock Units and stock options to Catalys Pacific Fund, LP.

Mineralys Therapeutics Director and 10% owner Srinivas Akkaraju reported planned future acquisitions of 6,200 Restricted Stock Units and 8,300 stock options.

Mineralys Therapeutics Director Derek DiRocco was granted 6,200 Restricted Stock Units and 8,300 stock options, which he holds for RA Capital Management funds.